Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis of an Imprinted Receptor Targeted for Sulfonated Aromatic Pollutants by a Stoichiometric Substructure Imprinting Approach.

Polymer science & technology (Washington, D.C.)·2026
Same author

Research priorities in the field of interprofessional healthcare education: a James Lind Alliance Priority Setting Partnership.

BMJ open·2026
Same author

A Synthetic Epitope-Binding Receptor Enables In Situ Recruitment of Endogenous Bioactive Ligand for Tissue Regeneration.

Angewandte Chemie (International ed. in English)·2026
Same author

Modifying Epigenetic Landscapes to Restore Immune Therapeutic Responses in Triple Negative Breast Cancer.

Cancers·2026
Same author

[Design and synthesis of molecularly imprinted polymers and their applications in medical diagnosis and biocatalysis].

Se pu = Chinese journal of chromatography·2026
Same author

Dummy Templated Receptors Showing Enhanced Affinity for Vitamin D3.

Molecules (Basel, Switzerland)·2026
Same journal

Pathology-Targeted Nanoparticles Guided by Peptide Remodel the Periodontal Microenvironment for Periodontitis Therapy.

Advanced healthcare materials·2026
Same journal

Gellan Gum Fluid Gel System for Controlled-Delivery of Cytokine-Licensed MSC-EVs to Enhance Corneal Repair in Limbal Stem Cell Deficiency.

Advanced healthcare materials·2026
Same journal

Diabetic Wound Healing Enabled by a Tri-Functional MAX Phase via Cu Doping.

Advanced healthcare materials·2026
Same journal

Plasmonically Reinforced Self-Sufficient Nanozymes Dysregulating Redox Homeostasis for Augmented Cascade Catalytic Oncotherapy.

Advanced healthcare materials·2026
Same journal

Spontaneous Helical Alignment of Smooth Muscle Cells to Form a Medial Layer for Engineered Microvasculature.

Advanced healthcare materials·2026
Same journal

Injectable Antifouling Adhesive Hydrogel Enables Robust Neural Interfaces for Stable ECoG Recording.

Advanced healthcare materials·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K

PSMA-Targeting Imprinted Nanogels for Prostate Tumor Localization and Imaging.

Tong Zhang1,2, Melanie Berghaus3, Yuan Li1

  • 1State Key Laboratory of Organic-Inorganic Composites, International Joint Bioenergy Laboratory of Ministry of Education, National Energy Research and Development Center for Biorefinery, Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China.

Advanced Healthcare Materials
|December 18, 2024
PubMed
Summary
This summary is machine-generated.

This study introduces novel synthetic antibodies, MIP-M, for targeting prostate-specific membrane antigen (PSMA) in prostate cancer. These nanogels offer improved stability, specificity, and production compared to traditional agents.

Keywords:
dispersed‐phase imprintingmolecularly imprinted nanogelsprostate cancerprostate‐specific membrane antigentissue imaging

More Related Videos

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.4K
Evaluation of Nanoparticle Uptake in Tumors in Real Time Using Intravital Imaging
08:04

Evaluation of Nanoparticle Uptake in Tumors in Real Time Using Intravital Imaging

Published on: June 21, 2011

18.3K

Related Experiment Videos

Last Updated: Jun 4, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.4K
Evaluation of Nanoparticle Uptake in Tumors in Real Time Using Intravital Imaging
08:04

Evaluation of Nanoparticle Uptake in Tumors in Real Time Using Intravital Imaging

Published on: June 21, 2011

18.3K

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Oncology

Background:

  • Prostate-specific membrane antigen (PSMA) is a key biomarker overexpressed in prostate cancer.
  • Existing PSMA-targeting agents like antibodies and small molecules have limitations including instability, complex production, low specificity, and high toxicity.
  • A novel synthetic antibody is needed to overcome these challenges for effective PSMA-directed cancer therapy.

Purpose of the Study:

  • To develop and characterize a novel PSMA-targeting synthetic antibody, MIP-M, to address limitations of conventional agents.
  • To evaluate the binding affinity, specificity, and targeting capability of MIP-M for PSMA.

Main Methods:

  • Synthesis of fluorescently labeled, N-isopropylacrylamide-based epitope imprinted nanogels (MIP-M) using magnetic nanoparticles as templates and a linear PSMA epitope.
  • Assessment of binding affinities to the epitope template and PSMA using established methods.
  • Evaluation of specificity against reference peptides and human serum albumin.
  • Flow cytometry and confocal laser scanning microscopy to compare MIP-M binding to prostate cancer cell lines (PC3 and LNCaP) with varying PSMA expression levels, alongside a PSMA antibody.

Main Results:

  • MIP-M demonstrated high binding affinities for both the epitope template (KD = 6 × 10-10 M) and PSMA (KD = 2.5 × 10-9 M).
  • MIP-M exhibited high specificity compared to reference peptides and human serum albumin.
  • Flow cytometry and microscopy confirmed comparable binding preferences of MIP-M and a PSMA antibody for LNCaP cells (high PSMA expression).
  • MIP-M showed selectivity for PSMA-positive prostate tumors over normal tissue, similar to the PSMA antibody.

Conclusions:

  • The developed MIP-M synthetic antibody effectively targets PSMA with high affinity and specificity.
  • MIP-M offers advantages over conventional agents by addressing limitations in stability, production, specificity, and toxicity.
  • MIP-M represents a promising alternative for PSMA-directed prostate cancer diagnosis and treatment.